.U.S. FDA Approves First Interchangeable Biosimilars to Treat Macular Degeneration and Other Eye Conditions

The FDA approved two interchangeable biosimilars for aflibercept (Eylea) to treat macular degeneration and other eye conditions.

More: bit.ly/3WYQDF4

The U.S. FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) as biosimilars to Eylea (aflibercept). For all the latest #DrugNews , check out our drug referential resource: ow.ly/FK9W50RWH7F.

The Food and Drug Administration (FDA) announced its approval of 2 biosimilars as interchangeable with aflibercept 2 mg (Eylea). All 3 products are anti-VEGF agents, administered intravitreally for nAMD.

Read more: modernretina.com/view/us-fda-is…

🔥Maintenance with 5FU/LV-Aflibercept after FOLFIRI-Aflibercept vs treatment until progression in older pts in 2nd line mCRC: #ESMO23
✅ AFEMA trial, age >70 yrs
👉ORR 20 vs 9%
👉mPFS 6.1 vs 5.5 mo
👉mOS 12.2 vs 11.5 mo
🧐non-inferiority for PFS shown, ORR & OS did not differ,

A #HighDoseAflibercept (8 mg) delivered every 12 or 16 weeks is noninferior to the standard #Aflibercept dosage of 2 mg delivered every 8 weeks for the treatment of #DiabeticMacularEdema (DME). Published in The Lancet

Read more: brnw.ch/21wJDf2

#DME #Ophthalmology

🚨 ICYMI 🚨

Mark R. Barakat, MD, discusses data on #IOP in patients receiving #aflibercept 8 mg for #diabeticmacularedema in the PHOTON trial compared with those receiving aflibercept 2 mg. 🎥👇
#OcularSurgeryNews #glaucoma #ARVO2024 ARVO
healio.com/news/ophthalmo…

Cuando le digo a un paciente que tiene una DMAE exudativa y que le tengo que poner un Aflibercept Intravítreo

High-dose Aflibercept Pushes Dosing Interval to Five Months

Nearly half of subjects went 20 weeks or longer between injections with the 8mg formulation. The regimen also maintained BCVA gains out to 96 weeks.
reviewofoptometry.com/article/highdo…
#eylea #amd #retina #eyecare #optometry

#Biocon biosimilar #Aflibercept receives interchangeable status from #USFDA , it is branded as #Yesafili . US FDA approves #Yesafili and #Opuviz as interchangeable biosimilars to #Eylea

Here's more

Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an OHDSI Network Study
ow.ly/UitT50QYGkr

Aflibercept | Biosimilar | Patent Settlement

Biocon Biologics secures Canada market entry date for
Yesafili® (Aflibercept), a proposed biosimilar to Eylea

Ref: Biocon March'24

Regeneron announced 1-year results from the pivotal PULSAR and PHOTON trials demonstrating Eylea HD (aflibercept injection 8 mg) extended dosing regimens were non-inferior to Eylea aflibercept injection 2 mg) for both the treatment of wet AMD and DME.

Biocon Biologics Receives U.S. FDA Approval for Biosimilar Aflibercept for Yesafili. Enters U.S. Ophthalmology Market.

The U.S. Food and Drug Administration (US FDA) has approved Biocon Biologics first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable

The Food and Drug Administration (FDA) announced its approval of 2 biosimilars as interchangeable with aflibercept 2 mg (Eylea). All 3 products are anti-VEGF agents, administered intravitreally for nAMD.

Read more: modernretina.com/view/us-fda-is…

The Kingfisher Study found that the visual outcomes after 1 year of brolucizumab, 6 mg, (Beovu, Novartis) in participants with diabetic macular edema (DME) did not differ significantly from those obtained with aflibercept

Read More: ophthalmologytimes.com/view/kingfishe…

Amongst patients with treatment-resistant nAMD, switching from aflibercept to faricimab may serve as a safe and effective option. Significant anatomical improvements were observed, with a trend towards visual stability. ow.ly/VMZ150Qf0hA

Regeneron Pharmaceuticals announced the publication of one-year results from the pivotal PULSAR and PHOTON trials for aflibercept 8 mg injection (Eylea HD).

Read More: ow.ly/FU3K50QOXO5

Enrollment has now been completed for Opthea Limited’s COAST Phase 3 clinical trial, which is investigating the use of sozinibercept (OPT-302) and aflibercept for the treatment of wet age-related macular degeneration.

Read more: ow.ly/WqC950QFbfZ

#CofeprisTransparente da a conocer el resultado del Comité de Moléculas Nuevas y del Subcomité de Evaluación de Productos Biotecnológicos sobre: Aflibercept recibiendo un resultado favorable 🧬

Prithu S. Mettu, MD, kicked off the sessions with a rundown of wet AMD therapies—new and still under investigation. Are you using faricimab or high-dose aflibercept yet? #DukefAVS #retina Duke Eye Center YoungMD Connect